ARA-290 (16mg) Research Peptide: An EPO‑Derived Agonist of the Innate Repair Receptor for Neuroprotection & Inflammation Studies

If your research investigates neuroprotection, tissue repair, or the modulation of inflammatory pathways, ARA-290 (16mg) research peptide — also known as cibinetide — offers a precisely defined and mechanistically distinct synthetic tool. ARA-290 is an 11‑amino‑acid synthetic peptide engineered to replicate the three‑dimensional structure of the helix B surface domain of erythropoietin (EPO).

Unlike full‑length EPO, which drives red blood cell production through the classical homodimeric EPO receptor, ARA-290 was specifically designed to bind selectively to the non‑haematopoietic EPO receptor — a heterodimeric complex of EPOR and the beta‑common receptor (βcR, CD131) termed the innate repair receptor (IRR). This receptor mediates EPO’s tissue‑protective and anti‑inflammatory effects while being pharmacologically separable from the erythropoietic pathway. This makes ARA-290 (16mg) research peptide a valuable tool for laboratories investigating neuroprotection, inflammation, tissue repair, and metabolic regulation without the confounding variable of erythropoiesis.

At Wuhan Top Miracle Peptides, we supply high‑purity ARA-290 (16mg) research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into neuroprotection, tissue repair, and inflammatory signalling begin with uncompromising quality.

What Is ARA-290 and How Does It Work?

To fully appreciate the research potential of ARA-290 (16mg) research peptide, it is essential to understand its biochemical design and the precise mechanism by which it exerts its tissue‑protective effects.

The 11‑Amino‑Acid EPO‑Derived Peptide

ARA-290 (cibinetide) is a synthetic linear peptide composed of 11 amino acids. Its sequence is {Glp}‑Glu‑Gln‑Leu‑Glu‑Arg‑Ala‑Leu‑Asn‑Ser‑Ser (shortened as {Glp}‑EQLERALNSS). Its molecular formula is C₅₁H₈₄N₁₆O₂₁, and its molecular weight is approximately 1257.31 g/mol. It has a CAS number of 1208243-50-8 and a PubChem CID of 91810664.

The peptide was engineered from the helix‑B surface of the EPO molecule, identifying an 11‑amino‑acid sequence that selectively activates the tissue‑protective receptor without binding the classical homodimeric EPOR. This separation of function — between erythropoietic and tissue‑protective activities — was a key scientific insight that enabled the development of ARA-290.

Mechanism of Action: Selective Innate Repair Receptor Agonism

The biological activity of ARA-290 (16mg) research peptide is mediated through its selective activation of the innate repair receptor (IRR):

• Receptor Targeting: ARA-290 binds selectively to the non‑haematopoietic EPO receptor, a heterodimeric complex composed of EPOR and the beta‑common receptor (βcR, CD131). This receptor is distinct from the classical homodimeric EPOR that drives erythropoiesis.

• Tissue Protection Without Erythropoiesis: By engaging the IRR, ARA-290 activates the tissue‑protective and anti‑inflammatory arm of the EPO signalling system without stimulating red blood cell production. This addresses the central challenge in EPO‑based research: achieving tissue‑protective effects without erythropoiesis.

• Anti‑Inflammatory and Anti‑Apoptotic Signalling: ARA-290 reduces inflammation and fibrosis, suppresses neuronal apoptosis, and mediates tissue protection through the β‑common receptor.

• Short Half‑Life, Sustained Effects: Despite a plasma half‑life of approximately 2 minutes, ARA-290 activates a molecular switch that triggers sustained biological effects observed in multiple preclinical models and clinical trials.

Research Note: The Innate Repair Receptor

The IRR is suggested to be a point of integration between the immune system and pain signalling (via nociception). ARA-290 was designed to bind the IRR selectively, and this receptor configuration — first described in a landmark 2004 study in PNAS — mediates EPO’s neuroprotective and cytoprotective effects.

Key Research Applications for ARA-290 (16mg)

ARA-290 (16mg) research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Neuroprotection & Ischaemic Research

ARA-290 has demonstrated significant neuroprotective effects in models of cerebral ischaemia. Research has demonstrated:

• Cerebral Ischaemic Stroke: ARA-290 exerts a neuroprotective action against cerebral ischaemic injury by suppressing neuronal apoptosis and inflammatory reactions in mice without motivating splenomegaly and erythropoiesis. The neuroprotective effect is mediated via the β‑common receptor.

• Neuropathic Pain: ARA-290 dose‑dependently reduced allodynia coupled to suppression of the spinal microglia response. Phase II trials in sarcoidosis‑associated small‑fiber neuropathy showed improvements in neuropathic pain scores and corneal nerve fibre density.

• Experimental Autoimmune Encephalomyelitis: ARA-290 demonstrated neuroprotective effects equivalent to EPO in a rat model of EAE.

2. Inflammation & Immune Modulation Research

ARA-290’s anti‑inflammatory properties make it a valuable tool for studying inflammatory signalling:

• Chronic Stress‑Induced Depression: ARA-290 ameliorated chronic stress‑induced depression‑like behaviour in mice through, at least partially, its anti‑inflammatory effects.

• Cardiac Inflammation: ARA-290 reduces cardiac inflammation, attenuates age‑associated declines in heart function, and prolongs healthspan.

• Inflammatory Pathway Suppression: ARA-290 mediates tissue protection by reducing inflammatory and fibrotic responses via signalling through the EPOR/CD131 heterodimeric receptor.

3. Metabolic & Diabetes Research

ARA-290 has been investigated for its effects on metabolic control:

• Type 2 Diabetes: ARA-290, a non‑erythropoietic peptide engineered from EPO, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

• Fat Mass and Glucose Tolerance: Non‑erythropoietic EpoR agonist ARA-290 decreased fat mass and increased glucose tolerance without increasing EPO‑stimulated erythropoiesis in mouse models.

4. Tissue Repair & Regenerative Research

ARA-290 has been studied for its tissue‑protective effects across multiple organ systems:

• Acute Kidney Injury: ARA-290 exerts beneficial effects in preclinical models of acute kidney injury.

• Emphysema: ARA-290 has demonstrated beneficial effects in models of emphysema.

• Endothelial Colony‑Forming Cells: ARA-290 enhances the proliferation, migration, and resistance to H₂O₂‑induced apoptosis of endothelial colony‑forming cells.

5. Frailty & Healthspan Research

ARA-290 has been studied for its potential to ameliorate frailty and preserve healthspan:

• Frailty Amelioration: Administration of ARA-290 reduces cell and tissue inflammation, mitigates structural and functional changes within the cardiovascular system, leading to amelioration of frailty and preserved healthspan.

Chemical & Physical Specifications

Accurate characterisation of ARA-290 (16mg) research peptide is essential for reproducible experimental design.

Note: The 16 mg mass refers to the weight of the peptide in its lyophilised form. ARA-290 is typically supplied as a TFA salt, which enhances aqueous solubility. The peptide has a plasma half‑life of approximately 2 minutes, but its protective effects are sustained through activation of the innate repair receptor.

Reconstitution & Handling Protocol for ARA-290 (16mg)

Proper reconstitution of ARA-290 (16mg) research peptide is critical for maintaining its structural integrity and biological activity.

Step 1 – Preparation

• Bring the sealed ARA-290 vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the ARA-290 vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 16 mg per 1.6 mL of diluent, yielding a 10 mg/mL stock solution.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted ARA-290 into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table

Adjust diluent volume based on your experimental requirements. For cell culture applications, typical working concentrations may range from 0.1‑10 µM.

Storage & Stability Guidelines

Why Choose Wuhan Top Miracle Peptides for ARA-290 (16mg)?

As an authentic licensed peptide supplier based in the United Kingdom, we supply ARA-290 (16mg) research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥98% for every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• UK‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO).

Researchers across the United Kingdom—including those at leading institutions in London, Cambridge, Oxford, Manchester, and Edinburgh—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: ARA-290 (16mg) Research Peptide

What is ARA-290 (16mg) research peptide?
ARA-290 (cibinetide) is a synthetic 11‑amino‑acid peptide engineered from the helix‑B surface domain of erythropoietin. It is designed to bind selectively to the innate repair receptor (IRR) — a heterodimer of EPOR and CD131 — to mediate tissue‑protective and anti‑inflammatory effects without erythropoiesis.

What is the sequence and molecular weight of ARA-290?
The sequence is {Glp}‑Glu‑Gln‑Leu‑Glu‑Arg‑Ala‑Leu‑Asn‑Ser‑Ser ({Glp}‑EQLERALNSS). Its molecular formula is C₅₁H₈₄N₁₆O₂₁, and its molecular weight is approximately 1257.31 g/mol.

What are the primary research applications for ARA-290?
ARA-290 is used in neuroprotection and ischaemic research (cerebral stroke, neuropathic pain), inflammation and immune modulation research, metabolic and diabetes research, tissue repair and regenerative research, and frailty and healthspan research.

What is the mechanism of action of ARA-290?
ARA-290 binds selectively to the innate repair receptor (IRR) — a heterodimer of EPOR and CD131 — activating the tissue‑protective and anti‑inflammatory arm of the EPO signalling system without stimulating red blood cell production.

How does ARA-290 differ from erythropoietin?
Unlike full‑length EPO, which drives erythropoiesis through the classical homodimeric EPOR, ARA-290 selectively engages the heterodimeric IRR to mediate tissue protection without erythropoiesis. It has a plasma half‑life of approximately 2 minutes but activates sustained protective effects.

What purity does your ARA-290 (16mg) meet?
Our ARA-290 is tested to ≥98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute ARA-290 (16mg)?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake. A typical starting concentration is 10 mg/mL.

How should I store reconstituted ARA-290?
Reconstituted ARA-290 should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

Is ARA-290 research peptide legal to purchase in the UK?
Yes. ARA-290 is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United Kingdom for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: As of April 2026, Araim Pharmaceuticals, the company that developed ARA-290, has closed operations, and no active IND or NDA exists. The compound is not FDA‑approved for human use.

Does Wuhan Top Miracle Peptides ship internationally?
Yes. We ship across the EU (France, Germany, Spain, Sweden, Italy) and to the USA from our UK warehouse. Wholesale pricing is available for bulk orders.

Wholesale ARA-290 16mg Supply Across the UK and Europe

Wuhan Top Miracle Peptides supports wholesale peptide buyers in the United Kingdom and international markets.

We Support Enquiries From:

• United Kingdom
• France
• Germany
• Spain
• Sweden
• Italy
• USA
• Wider Europe

For larger ARA-290 16mg enquiries, contact our team before ordering. This helps confirm stock, documentation, shipping options, product identity, and buyer verification requirements.

Where to Source ARA-290 16mg in the UK

If you are searching for where to source ARA-290 16mg in the UK, Wuhan Top Miracle Peptides provides a simple professional enquiry process.

Professional Enquiry Process

1. Review the ARA-290 16mg product details.
2. Check the current label and batch information.
3. Confirm whether the batch is listed as ARA-290, ARA290, Cibinetide, pHBSP, or another verified identity.
4. Ask about COA and purity-related documentation.
5. Confirm the sequence and salt form where required.
6. Confirm your shipping country.
7. Discuss wholesale quantity requirements.
8. Complete buyer verification where required.
9. Place a professional enquiry with support from our team.

 

Bulk Peptides Page
Shipping & Returns Page
Contact Us Page
Shop Page
Quality / Compliance Page
SS-31 Product Page
Humanin Product Page
PubChem / compound reference source
Scientific or peptide reference source
GOV.UK / MHRA
Google Search Central
ASA / CAP Code Section 12

From its origin as an engineered fragment of the helix‑B domain of erythropoietin to its well‑characterised role as a selective agonist of the innate repair receptor, ARA-290 (16mg) research peptide provides a precisely defined and mechanistically distinct platform for advanced neuroprotection, inflammation, and tissue repair research.

Its ability to engage the tissue‑protective arm of the EPO signalling system without erythropoiesis — supported by peer‑reviewed research published in PNAS, Science, and other authoritative journals — makes it a valuable addition to any laboratory investigating neuroprotection, inflammatory signalling, or tissue regeneration. By choosing high‑purity, lab‑verified ARA-290 (16mg) research peptide from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with ARA-290 (16mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade ARA-290 delivered directly to your facility in the UK, EU, or USA.